A cancer vaccine appears to significantly improve survival in people in remission from one of the most common and aggressive blood cancers, acute myeloid leukemia (AML), according to new results from a phase 3 clinical trial.
The vaccine, galinpepimut-S (or GPS), was invented by David A. Scheinberg, MD, PhD, a leader in immunotherapy drug development at Memorial Sloan Kettering Cancer Center (MSK).
The clinical trial, which included 126 patients, was led by SELLAS Life Sciences Group. The study found:
- The vaccine reduced the risk of death by 41%.
- The median overall survival was 24.0 months in those receiving the vaccine, compared with 14.7 months for patients on standard treatments — a difference of 9 months.
- The vaccine appeared safe, with minimal side effects – most commonly reactions at the injection site.
As a therapeutic cancer vaccine, it works by teaching the immune system to fight remaining traces of cancer cells that may be undetectable following treatment, but ultimately can lead to a relapse.
The GPS is a complex “peptide” vaccine that triggers a targeted immune response by using synthetic peptides, which are the building blocks of proteins. The vaccine targets a protein called WT1, found in the cancer cells of more than 95% of people with AML (as well as in ovarian cancer, mesothelioma, and other cancers and leukemias).
The GPS vaccine is ready-made and “off-the-shelf” — as opposed to a personalized vaccine individually designed for each patient. Because off-the-shelf vaccines don’t need to be custom-manufactured, the hope is that they can be mass-produced, stored, and administered right away.
“Two decades of research have given us a much clearer picture of how the immune system can recognize and attack tumors and leukemias,” Dr. Scheinberg says. “These insights are helping lay the groundwork for these exciting, new immune-based approaches that could safely benefit more people with cancer. These data bring us closer to having the first off-the-shelf vaccine for AML patients.”
A pressing need for better treatments
Although rare overall, acute myeloid leukemia is one of the most common types of blood cancer. It moves quickly and needs aggressive, often harsh, treatment with chemotherapy, sometimes followed by a bone marrow transplant. Even when these therapies stop the cancer, AML often returns, and treatment options have been limited.
The trial’s results point to the potential of GPS as a completely new form of “maintenance immunotherapy,” which prevents the disease from returning after primary treatment. Dr. Scheinberg and his colleagues at MSK have been developing this peptide vaccine for more than two decades.
Dr. Scheinberg holds the Vincent Astor Chair.
Disclosure: Memorial Sloan Kettering (MSK) and Dr. Scheinberg have financial interests related to SELLAS Life Sciences.